Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will
report its second quarter 2009 financial results on Thursday, July 23,
2009, after the close of financial markets. Following the announcement,
company management will host a conference call and webcast discussion of
the results and provide a general corporate update. Access to the event
can be obtained as follows:
LIVE access on Thursday, July 23, 2009, 2:00 p.m. Pacific Time (PT) /
5:00 p.m. Eastern Time (ET)
-
Telephone (877) 941-8610 (domestic) or (480) 629-9818 (international);
conference ID 4114066
-
Webcast available at www.seattlegenetics.com
in the News and Investor Information section
REPLAY access
-
Telephone replay will be available beginning at approximately 4:00
p.m. PT on July 23, 2009 through 4:00 p.m. PT on July 27, 2009 by
calling (800) 406-7325 (domestic) or (303) 590-3030 (international);
conference ID 4114066
-
Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com
in the News and Investor Information section
About Seattle Genetics
Seattle Genetics is a clinical stage biotechnology company focused on
the development and commercialization of monoclonal antibody-based
therapies for the treatment of cancer and autoimmune disease. The
company’s lead product candidate, SGN-35, is in a pivotal trial under a
special protocol assessment with the FDA. SGN-35 is empowered by Seattle
Genetics’ proprietary antibody-drug conjugate (ADC) technology
comprising highly potent synthetic drugs and stable linkers for
attaching the drugs to monoclonal antibodies. In addition, Seattle
Genetics has three other product candidates in ongoing clinical trials:
dacetuzumab (SGN-40), lintuzumab (SGN-33) and SGN-70. Dacetuzumab is
being developed under a worldwide collaboration with Genentech (a
wholly-owned member of the Roche Group). Seattle Genetics has
collaborations for its ADC technology with a number of leading
biotechnology and pharmaceutical companies, including Genentech, Bayer,
CuraGen, Progenics, Daiichi Sankyo, MedImmune, a subsidiary of
AstraZeneca, and Millennium: The Takeda Oncology Company, as well as an
ADC co-development agreement with Agensys, a subsidiary of Astellas
Pharma. More information can be found at www.seattlegenetics.com.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
